Home » Eli Lilly’s Retevmo Approved for Lung and Thyroid Cancers
Eli Lilly’s Retevmo Approved for Lung and Thyroid Cancers
The FDA has granted accelerated approval to Eli Lilly’s Retevmo (selperactinib) for patients with advanced RET-driven, non-small cell lung cancer, medullary thyroid cancer and other types of thyroid cancers.
Retevmo is a selective RET kinase inhibitor that can block mutations which account for the majority of medullary thyroid cancers.
The fast-track approval was based on the results of a phase 1/2 clinical trial in more than 700 patients, the largest-ever study of patients with RET-driven cancers.
Retevmo was granted priority review, breakthrough therapy and orphan drug designations.
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May